RVU120 (CDK8/19 inhibitor): Acceptable safety profile and two clinically relevant responses were observed in the Ph I dose escalation study in the first five AML and high risk MDS patients treated: one complete response (CR) and one erythroid response
SEL24/MEN1703…
Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology Association. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini
Share this article
More News
Can Robinhood’s Crypto.com Deal Supercharge Prediction Markets’ Growth?
September 9, 2026
Prediction: This Will Be Apple’s Stock Price by the End of 2027
September 9, 2026
Will this fuel crypto’s 2024-style rally?
September 9, 2026
Meta Platforms (META) Sued Over AI Tuned Crypto Scam Ads
September 9, 2026
Trump oil investments have gained millions during Iran war
September 9, 2026